Yu Tang

Yu Tang

Auto-generated profile, based on publicly available information

Yu Tang

Hunan Cancer Hospital, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
NXNing Xie
Ning Xie
XHXiaobo Hu
Xiaobo Hu
YTYu Tang
Yu Tang
CTCan Tian
Can Tian
YHYing He
Ying He
QOQuchang Ouyang
Quchang Ouyang
Objectives Although primary tumour surgery could prolong survival for patients with stage IV breast cancer, how to select candidates for primary tumour surgery is still a challenging problem for medical oncologists. Design This study is a retrospective database study. Setting and participants In this study, we aimed at evaluating the primary site surgery effect and select the beneficial subgroups. 13 618 patients with stage IV breast cancer, diagnosed between 2010 and 2015, were collected from SEER*Stat database. Interventions Based on the local surgery at primary tumour site, patients were categorised into three groups: primary tumour surgery performed group, recommended for primary tumour surgery but refused (RBR) group and surgery not recommended (NR) group. Primary and secondary outcome measures All-cause survival and breast cancer-specific survival (BCSS). Results Univariate Cox regression analyses showed that, compared with surgery group, patients in non-surgery (RBR and NR) groups tend to be older, T4, N0/NX, triple-negative and visceral metastatic. For both all-cause survival and BCSS, non-surgery, advanced T stage, triple-negative BC (TNBC) and visceral metastases were significant risk factors. Primary tumour surgery showed benefits for both all-cause survival (HR=0.44, 95% CI=0.39–0.49, p<0.0001) and BCSS (HR=0.43, 95% CI=0.38–0.49, p<0.0001). However, after propensity score matching, primary tumour surgery failed to demonstrate significant benefits for TNBC (HR=0.96, 95% CI=0.60–1.53, p=0.851) and patients with visceral metastases (HR=0.90, 95% CI=0.60–1.36, p=0.62). Conclusion Surgery was associated with prolonged survival in stage IV breast cancers, but not in patients with TNBC and visceral metastases.